» Articles » PMID: 21918631

A Kinetic Platform for in Silico Modeling of the Metabolic Dynamics in Escherichia Coli

Overview
Publisher Dove Medical Press
Specialty Chemistry
Date 2011 Sep 16
PMID 21918631
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Background: A prerequisite for a successful design and discovery of an antibacterial drug is the identification of essential targets as well as potent inhibitors that adversely affect the survival of bacteria. In order to understand how intracellular perturbations occur due to inhibition of essential metabolic pathways, we have built, through the use of ordinary differential equations, a mathematical model of 8 major Escherichia coli pathways.

Results: Individual in vitro enzyme kinetic parameters published in the literature were used to build the network of pathways in such a way that the flux distribution matched that reported from whole cells. Gene regulation at the transcription level as well as feedback regulation of enzyme activity was incorporated as reported in the literature. The unknown kinetic parameters were estimated by trial and error through simulations by observing network stability. Metabolites, whose biosynthetic pathways were not represented in this platform, were provided at a fixed concentration. Unutilized products were maintained at a fixed concentration by removing excess quantities from the platform. This approach enabled us to achieve steady state levels of all the metabolites in the cell. The output of various simulations correlated well with those previously published.

Conclusion: Such a virtual platform can be exploited for target identification through assessment of their vulnerability, desirable mode of target enzyme inhibition, and metabolite profiling to ascribe mechanism of action following a specific target inhibition. Vulnerability of targets in the biosynthetic pathway of coenzyme A was evaluated using this platform. In addition, we also report the utility of this platform in understanding the impact of a physiologically relevant carbon source, glucose versus acetate, on metabolite profiles of bacterial pathogens.

Citing Articles

Validated In Silico Population Model of .

Rajagopal S, Hmar R, Mookherjee D, Ghatak A, Shanbhag A, Katagihallimath N ACS Synth Biol. 2022; 11(8):2672-2684.

PMID: 35801944 PMC: 9397402. DOI: 10.1021/acssynbio.2c00097.


Genome-wide gene expression tuning reveals diverse vulnerabilities of M. tuberculosis.

Bosch B, DeJesus M, Poulton N, Zhang W, Engelhart C, Zaveri A Cell. 2021; 184(17):4579-4592.e24.

PMID: 34297925 PMC: 8382161. DOI: 10.1016/j.cell.2021.06.033.


Validation of CoaBC as a Bactericidal Target in the Coenzyme A Pathway of Mycobacterium tuberculosis.

Evans J, Trujillo C, Wang Z, Eoh H, Ehrt S, Schnappinger D ACS Infect Dis. 2016; 2(12):958-968.

PMID: 27676316 PMC: 5153693. DOI: 10.1021/acsinfecdis.6b00150.


Overexpression of Bcl-2 induces STAT-3 activation via an increase in mitochondrial superoxide.

Kang J, Chong S, Ooi V, Vali S, Kumar A, Kapoor S Oncotarget. 2015; 6(33):34191-205.

PMID: 26430964 PMC: 4741445. DOI: 10.18632/oncotarget.5763.


In silico-based high-throughput screen for discovery of novel combinations for tuberculosis treatment.

Singh R, Ramachandran V, Shandil R, Sharma S, Khandelwal S, Karmarkar M Antimicrob Agents Chemother. 2015; 59(9):5664-74.

PMID: 26149995 PMC: 4538536. DOI: 10.1128/AAC.05148-14.


References
1.
Ishii N, Nakahigashi K, Baba T, Robert M, Soga T, Kanai A . Multiple high-throughput analyses monitor the response of E. coli to perturbations. Science. 2007; 316(5824):593-7. DOI: 10.1126/science.1132067. View

2.
Payne D, Gwynn M, Holmes D, Pompliano D . Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov. 2006; 6(1):29-40. DOI: 10.1038/nrd2201. View

3.
Singh V, Ghosh I . Kinetic modeling of tricarboxylic acid cycle and glyoxylate bypass in Mycobacterium tuberculosis, and its application to assessment of drug targets. Theor Biol Med Model. 2006; 3:27. PMC: 1563452. DOI: 10.1186/1742-4682-3-27. View

4.
Baba T, Ara T, Hasegawa M, Takai Y, Okumura Y, Baba M . Construction of Escherichia coli K-12 in-frame, single-gene knockout mutants: the Keio collection. Mol Syst Biol. 2006; 2:2006.0008. PMC: 1681482. DOI: 10.1038/msb4100050. View

5.
Feist A, Henry C, Reed J, Krummenacker M, Joyce A, Karp P . A genome-scale metabolic reconstruction for Escherichia coli K-12 MG1655 that accounts for 1260 ORFs and thermodynamic information. Mol Syst Biol. 2007; 3:121. PMC: 1911197. DOI: 10.1038/msb4100155. View